Skip to main content

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

Explore URMC
menu

Ajay Dhakal, M.B.B.S.

Contact Information

Phone Numbers

Appointment: (585) 487-1700

Administrative: (585) 486-0557

Fax: (585) 321-1724

URMFGA member of the University of Rochester Medical Faculty Group

groupAn Accountable Health Partner

assignmentAccepting New Patients

Faculty Appointments

Patient Care Setting

Cancer

Biography

Dr. Ajay Dhakal received his medical degree and completed his internship at Kathmandu Medical College in Kathmandu, Nepal in 2009. Dr. Dhakal then finished his residency at Maimonides Medical Center in Brooklyn, New York in 2015. He then completed a clinical fellowship at Roswell Park Comprehensive Cancer Center in Buffalo, New York in 2018.

Dr. Dhakal's special interest is breast cancer. His goal is to help breast cancer patients live longer with a good quality of life. Dr. Dhakal is passionate about conducting clinical research to better understand cancer biology and to discover new ways to treat breast cancer.

In his free time, Dr. Dhakal likes to travel and watch movies.

Credentials

Specialties

  • Hematology - American Board of Internal Medicine
  • Internal Medicine - American Board of Internal Medicine
  • Medical Oncology - American Board of Internal Medicine

Education

2009
MBBS | Kathmandu Medical College

Post-doctoral Training & Residency

07/01/2015 - 06/30/2018
Fellowship in Hematology/Oncology at Roswell Park Cancer Institute

07/01/2013 - 06/30/2015
Residency in Internal Medicine at Maimonides Medical Center

07/01/2012 - 06/30/2013
Internship in Internal Medicine at Maimonides Medical Center

VIEW ALL expand_more

Awards

2017 - 2018
Nominated for Gerald L. Logue Memorial Travel Award
Sponsor: Roswell Park Comprehensive Cancer Center,
Location: Buffalo, NY

2017
Best Poster, Annual Research Day
Sponsor: Jacobs School of Medicine and Biomedical Sciences
Location: University at Buffalo, Buffalo, NY

2014
Resident-Rock Award
Sponsor: Maimonides Medical Center
Location: Brooklyn, NY

2005
Dean's List in Basic Science Final Examinations
Sponsor: Kathmandu Medical College
Location: Nepal

2003 - 2009
Ministry of Education Scholarship
Sponsor: Kathmandu Medical College
Location: Nepal

VIEW ALL expand_more

Clinical Trials

(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response

Lead Researcher: Ajay Dhakal

This trial studies how well paclitaxel, trastuzumab, and pertuzumab work in eliminating further chemotherapy after surgery in patients with HER2-positive stage II-IIIa breast cancer who have no cancer remaining at surgery (either in the breast or underarm lymph nodes) after pre-operative chemotherapy and HER2-targeted therapy. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Trastuzumab and pertuzumab are both a form of "targeted therapy" because they work by attaching themselves to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When these drugs attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Giving paclitaxel, trastuzumab, and pertuzumab may enable fewer chemotherapy drugs to be given without compromising patient outcomes compared to the usual treatment.`

View Study Details

A Pilot Study of the Combination of Entinostat with Capecitabine in Metastatic and High Risk Breast Cancer after Neo-adjuvant Therapy

Lead Researcher: Ajay Dhakal

The purpose of this study is to learn about the safety and side effects of combining entinostat, an investigational drug, with capecitabine, a drug commonly used in breast cancer (BC) - in both participants with metastatic breast cancer (MBC) and then participants with high-risk breast cancer after neo-adjuvant therapy.

View Study Details

MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Lead Researcher: Ajay Dhakal

The purpose of this registry is to create a large-scale, population-based database. This database will match health information to genome data to identify new gene associations in breast cancer. The study will look at Agendia Breast Cancer tests, including MammaPrint® and BluePrint™, which are tests that help doctors analyze and profile breast cancer tumors.

View Study Details

NRG-BR004: A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer

Lead Researcher: Ajay Dhakal

This randomized phase III trial studies how well paclitaxel, trastuzumab, and pertuzumab with or without atezolizumab works in treating patients with breast cancer that has spread to other parts of the body. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with trastuzumab, pertuzumab, and atezolizumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether giving paclitaxel, trastuzumab, and pertuzumab with or without atezolizumab may kill more tumor cells.

View Study Details

A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently With Radiotherapy Versus Radiotherapy Alone for Inflammatory Breast Cancer (S1706)

Lead Researcher: Ajay Dhakal

This phase II trial studies how well radiation therapy with or without olaparib works in treating patients with inflammatory breast cancer. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether radiation therapy with or without olaparib may work better in treating patients with inflammatory breast cancer.

View Study Details

Publications

Journal Articles

7/15/2020
Moftakhar B, Lekkala M, Strawderman M, Smith TC, Meacham P, Fitzgerald B, Falkson CI, Dhakal A. "Impact of early dose intensity reduction of Palbociclib on clinical outcomes in patients with hormone-receptor-positive metastatic breast cancer." Breast cancer research and treatment.. 2020 Jul 15; Epub 2020 Jul 15.

2020
Moftakhar B, Kharel P, Niraula S, Gandhi S, Falkson C, Dhakal A. "Neratinib-Induced Duodenal Ulcer: A Case Report." Breast cancer : basic and clinical research.. 2020 14:1178223420935871. Epub 2020 Jun 23.

2020
Dhakal A, Antony Thomas R, Levine EG, Brufsky A, Takabe K, Hanna MG, Attwood K, Miller A, Khoury T, Early AP, Soniwala S, O'Connor T, Opyrchal M. "Outcome of Everolimus-Based Therapy in Hormone-Receptor-Positive Metastatic Breast Cancer Patients After Progression on Palbociclib." Breast cancer : basic and clinical research.. 2020 14:1178223420944864. Epub 2020 Jul 23.

Books & Chapters

2006
Book Title: Angel's Concise Clinical Methods,
Author List: Dhakal A, Magar A, Shrestha S, Shrestha R, Palikhey S
Published By: Makalu Publication House 2006 in Nepal

VIEW ALL PUBLICATIONS